

AMENDMENTS TO THE CLAIMS

1. (Cancelled)

2. (Currently amended) A drug combination for proliferating non-human animal natural killer cells which comprises lactoferrin as a first agent and Toll-like receptor ligand~~polyinosinic-polycytidylic acid~~ as a second agent, wherein the first agent comprises divided doses for 5 to 10~~7~~ days in an amount of 10 to 2000 mg/day/kg body weight ~~in terms of the amount of lactoferrin, and the second agent comprises one dose at 5 days after beginning of administration of the first agent~~ in an amount of 10 to 1000 μ g/day/kg body weight ~~in terms of the amount of the Toll-like receptor ligand.~~

3. (Currently amended) The drug combination for proliferating non-human animal natural killer cells according to claim 2, wherein the dosage form of the first agent comprising lactoferrin is for oral administration, and the dosage form of the second agent comprising the polyinosinic-polycytidylic acid~~Toll-like receptor ligand~~ is for intraperitoneal administration.

4. (Cancelled)

5. (Withdrawn-Currently amended) A method for proliferating natural killer cells in ~~an-a~~ non-human animal, which comprises administering the drug combination of claim 2 to ~~an-the~~ non-human animal, wherein lactoferrin is administered every day for 7 days in an amount of 10 to 2000 mg/day/kg body weight, and the polyinosinic-polycytidylic acid is administered in one dose 5 days after beginning of administration of lactoferrin in an amount of 10 to 1000 μ g/day/kg body weight.

6. (Cancelled)

7. (Withdrawn-Currently amended) The method for proliferating natural killer cells according to claim 5, wherein lactoferrin is orally administered, and the polyinosinic-polycytidylic acid~~Toll-like receptor ligand~~ is intraperitoneally administered.

8. (Cancelled)

9. (Withdrawn-Currently amended) A method for producing natural killer cells, which comprises administering the drug combination of claim 2 to ~~an-a non-human~~ animal, and collecting natural killer cells from the ~~non-human~~ animal, ~~wherein lactoferrin is administered every day for 7 days in an amount of 10 to 2000 mg/day/kg body weight, and the polyinosinic-polycytidylic acid is administered in one dose 5 days after beginning of administration of lactoferrin in an amount of 10 to 1000 µg/day/kg body weight.~~

10. (Cancelled)

11. (Withdrawn-Currently amended) The method for producing natural killer cells according to claim 9, wherein lactoferrin is orally administered, the ~~polyinosinic-polycytidylic acid~~^{Toll-like receptor ligand} is intraperitoneally administered, and natural killer cells are collected from the peritoneal cavity.

12-17. (Cancelled)

18. (Withdrawn-Currently amended) A method of producing the drug combination of claim 2, which comprises packaging a first agent containing lactoferrin ~~in five doses of 10 to 2000 mg/day/kg body weight and packaging~~ a second agent containing ~~polyinosinic-polycytidylic acid as a single dose in an amount of 10 to 1000 µg/day/kg body weight~~^{Toll-like receptor ligand}, wherein the first agent and the second agent are separately packaged.

19. (Cancelled)

20. (Withdrawn-Currently amended) The method according to claim 18, wherein the first agent containing lactoferrin is packaged for oral administration, and the second agent containing

Application No.: 10/573,564
Filing Date: March 27, 2006

| polyinosinic-polycytidylic acid Toll-like receptor ligand is packaged for intraperitoneal administration.

21-22. (Cancelled)